drugset / Trial / NCT04167761
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
NaSingle-groupOpen-labelBasic science
Summary
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.
Timeline
- Start
- 2020-07-01
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ertugliflozin | Unknown | 25 unknown | — |